Also available on ScienceDirect
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Mathieu Uzzan
Mo1557 COMPARISON OF EFFECTIVENESS BETWEEN VEDOLIZUMAB AND FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS PREVIOUSLY EXPOSED TO AT LEAST ONE ANTI-TNF AGENT: RESULTS FROM THE REAL-WORLD EVIDENCE MULTICENTER VEDOFIL STUDY
Also available on ScienceDirect
Mo1553 COMPARATIVE EFFECTIVENESS OF ADVANCED THERAPIES BETWEEN ULCERATIVE PROCTITIS AND MORE EXTENSIVE FORMS OF ULCERATIVE COLITIS: RESULTS FROM A MULTICENTER REAL-WORLD STUDY
Also available on ScienceDirect
Mo1556 COMPARISON OF EFFECTIVENESS BETWEEN USTEKINUMAB AND UPADACITINIB IN PATIENTS WITH ULCERATIVE COLITIS PREVIOUSLY EXPOSED TO AT LEAST ONE ANTI-TNF AGENT: RESULTS FROM THE REAL-WORLD EVIDENCE MULTICENTER UPPERCUT STUDY.
Also available on ScienceDirect
Tu1658 ONE-YEAR EFFICACY OF UPADACITINIB IN PERIANAL CROHN’S DISEASE: A MULTICENTER COHORT STUDY.
Cookie Preference Center We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
Editorial: JAK to JAK—Navigating Intra‐Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply
We thank Clough et al. for their editorial, which highlights the importance of the real-world data we generated on intra-class Janus kinase inhibitors (JAKi) switching [1, 2]. It is also important to note that this strategy may be of interest for patients with difficult-to-treat inflammatory bowel disease (IBD), although most currently available evidence assessed the switch from tofacitinib to upadacitinib [3].
Letter: Toward Intra‐Class Switching With JAK Inhibitors?
Akiyama et al. reported the real-world effectiveness of three JAK inhibitors in a Japanese multicentre cohort of 602 patients with ulcerative colitis (UC); 228, 215 and 159 patients, respectively, were treated with upadacitinib, filgotinib and tofacitinib [1]. Among these patients, 106 (46%) in the upadacitinib group, 30 (14%) in the filgotinib group and none in the tofacitinib group had prior exposure to another JAK inhibitor.
Early ileal resection in Crohn's disease is not associated with severe long‐term outcomes: The ERIC study
1 INTRODUCTION Crohn's disease (CD) is a lifelong inflammatory disease affecting an increasing number of patients worldwide.1, 2 All segments of the gastrointestinal tract can be affected. The disease is limited to the terminal ileum in about one-third of the patients at diagnosis with a non-stricturing and non-penetrating disease for most of them.3 However, about 20% of patients have a complicated disease at diagnosis that may lead to early surgery.
Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis
Research Article INFLAMMATORY BOWEL DISEASE Pablo Canales-Herrerias https://orcid.org/0000-0002-1865-6476, Mathieu Uzzan https://orcid.org/0000-0002-7761-2879, [...] , Akihiro Seki https://orcid.org/0000-0002-0356-1810, Rafael S. Czepielewski https://orcid.org/0000-0002-2475-3838, [...] , Bram Verstockt https://orcid.org/0000-0003-3898-7093, Alexandra E.
Review article: Updated management of acute severe ulcerative colitis: From steroids to novel medical strategies
Infliximab or ciclosporin: Considerations for the choice of treatment As seen previously, infliximab and ciclosporin have both proved effective for the management of ASUC. The selection of second-line therapies can be influenced by clinicians' habits, patients' features, safety, or efficacy concerns. While CNIs can induce a swift response, infliximab is usually favored due to fewer monitoring and better safety profile.
Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitis
Thank you for your interest in spreading the word about bioRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. Message Subject (Your Name) has forwarded a page to you from bioRxiv Message Body (Your Name) thought you would like to see this page from the bioRxiv website.
Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort
ORIGINAL ARTICLE Mathieu Uzzan, Corresponding Author mathieu.uzzan@aphp.fr orcid.org/0000-0002-7761-2879 Clichy, France Correspondence Mathieu Uzzan, Hopital Beaujon, Service de Gastroentérologie, MICI et Assistance Nutritive, 100 Boulevard du Général Leclerc, 92110 Clichy, France.
Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1-infected individuals
Eradicating HIV in infected patients likely requires disrupting the reservoir of infected T cells in the gastrointestinal tract. One way to accomplish this is by targeting cells expressing the α4β7, which has been tested in SIV models and is an approved therapy for inflammatory bowel disease. Uzzan and colleagues studied a small cohort of HIV-infected individuals on antiretroviral therapy that began anti-α4β7 treatment for their mild inflammatory bowel disease.
Colonic MicroRNA Profiles, Identified by a Deep Learning Algorithm, That Predict Responses to Therapy of Patients With Acute Severe Ulcerative Colitis
Background Acute severe ulcerative colitis is a severe condition without early predictors of response to medical treatments. Abnormal microRNA expression patterns in several human diseases, including ulcerative colitis, suggest a potential for use as a predictive biomarker of drug response.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Mathieu
Contact Mathieu, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack